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Abstract
Background: The Xpert MTB/RIF assay (Xpert assay; Cepheid, Sunnyvale, CA) is becoming the test of choice for the
rapid diagnosis of tuberculosis and rifampin (RIF) resistance. The aim of this study was to evaluate the performance
of the Xpert assay with respect to its clinical application at a tertiary care hospital in Korea, a country with an
intermediate tuberculosis burden and high-resource.
Methods: A total of 303 Xpert assay results from 109 smear-positive and 194 smear-negative respiratory specimens
were retrospectively reviewed. Based on patients’ medical records, four categories of clinical applications of the
Xpert assay were identified: (1) the diagnosis of pulmonary tuberculosis in patients with a high probability of pulmonary
tuberculosis according to their clinical and radiological features; (2) the exclusion of tuberculosis in clinically indeterminate
patients for pulmonary tuberculosis; (3) the differentiation of Mycobacterium tuberculsosis (MTB) from nontuberculous
mycobacteria in a smear-positive specimen; and (4) the diagnosis of RIF resistance. Standard culture and drug
susceptibility tests were used as reference methods.
Results: The sensitivity of the Xpert assay for MTB detection in category 1 was 89.8% (95% confidence interval [CI],
78.5-95.8%), but 66.7% (95% CI, 12.5-98.2%) in category 2. The positive predictive values ranged from 33.3% (95% CI,
6.0-75.9%) in category 2 to 91.3% and 91.7% in categories 1 and 3, respectively. The negative predictive values were
over 90% in all categories. The Xpert assay correctly detected RIF resistance in six of the seven (85.7%) isolates tested.
Conclusions: The Xpert assay exhibited variable performance according to its clinical application; this finding cautions
that careful interpretation for the results of this assay would be needed according to its intended purpose.
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Background
The Xpert MTB/RIF assay (Xpert assay; Cepheid, Sunnyvale,
CA) is a fully automated, cartridge-based, real-time
polymerase chain reaction (PCR) assay designed to detect
the presence of Mycobacterium tuberculosis (MTB) and
rifampin (RIF) resistance within 2 hours [1,2]. The Xpert
assay can not only be utilized as a rapid diagnostic test for
tuberculosis in patients with presumptive pulmonary
tuberculosis, but also can be used to rapidly exclude tuber-
culosis (e.g., for determining airborne infection isolation
discontinuation) or to differentiate MTB from non-
tuberculous mycobacteria (NTM) in smear-positive cases.
In addition, this assay may be used to determine whether
a patient with tuberculosis is infected with a RIF-resistant
strain [3-6].
According to the 2013 World Health Organization Glo-
bal Tuberculosis Report, South Korea is classified as a
high-income country with an intermediate tuberculosis
burden, including an incidence rate of 108 per 100,000 in-
habitants in 2013 and 1,212 cases of confirmed multidrug-
resistant tuberculosis reported in 2012 [7]. The accuracy
of the Xpert assay and its effectiveness in the rapid diag-
nosis of tuberculosis have both been demonstrated in pre-
vious studies [3-5,8-11]. However, the performance of the
Xpert assay has not yet been assessed in an intermediate-
incidence, high-resource setting with respect to its differ-
ent applications [9-11].
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In this study, we retrospectively evaluated the per-
formance of the Xpert assay according to its clinical ap-
plication in a tertiary care hospital in South Korea.
Methods
Study design
This study was conducted at Samsung Medical Center,
Seoul, South Korea, and the study protocol was approved
by the Institutional Review Board (#2014-05-029). A total
of 398 respiratory specimens were evaluated consecutively
using the Xpert assay between Oct. 2012 and Feb. 2014,
and the results were retrospectively analyzed. Samples
from patients from whom mycobacterial cultures were not
requested at the same day and nonrespiratory specimens
were excluded from this study (Figure 1).
Patient medical records and microbiological test results,
including acid-fast bacilli (AFB) smear, mycobacterial
culture, and drug susceptibility testing (DST) were
reviewed. Based on patient medical records, the samples
were divided into four different categories based on the
desired clinical application of the Xpert assay. Cases were
categorized independently by two doctors. Disagreement
in the interpretation of data required final consensus be-
tween both doctors. Category 1 consisted of samples from
patients with a high probability of pulmonary tuberculosis,
for whom rapid diagnosis of tuberculosis was required.
Presumptive pulmonary tuberculosis was defined as the
presence of the clinical symptoms (cough, fever, night
sweats, or weight loss) and radiologic findings compatible
with tuberculosis, in either a chest X-ray or a computed
tomography scan. All patients with a high probability of
pulmonary tuberculosis had both clinical and radiologic
features highly indicative of tuberculosis; moreover, these
features were unlikely to be caused by another disease.
Category 2 consisted of samples from patients that the
diagnosis of pulmonary tuberculosis was neither highly
probable nor reliably excluded by clinicians. The patients
in this clinically indeterminate group were asymptomatic
or did not have radiologic features highly suggestive of tu-
berculosis. Category 3 consisted of samples from patients
with an AFB smear-positive specimen, for which MTB
needed to be differentiated from NTM. The Xpert assay
was performed as add-on test in this category. Category 4
consisted of samples from patients with risk of multidrug-
resistant tuberculosis such as previously treated tubercu-
losis or no improvement despite standard tuberculosis
treatment.
Xpert MTB/RIF G4 assays
For the Xpert assay, either 1 mL of respiratory specimen
(without decontamination) or 0.5 mL of respiratory spe-
cimen sediment prepared according to the N-acetyl-l-
cysteine–NaOH (NALC-NaOH) method was used [12].
The Xpert assay was conducted according to the manu-
facturer’s instructions, as described previously [3].
Mycobacterial staining and culture
Acid-fast staining was performed with an auramine-
rhodamine fluorescent stain, followed by confirmation
with Ziehl-Neelsen staining. Staining results were graded
according to the US Centers for Disease Control recom-
mendations. Specimens in which the AFB smear results
were categorized as grades 1 to 4 were defined as smear-
positive [13]. All patient specimens were cultured on two
different types of media, solid and liquid, for 6 weeks.
To this end, decontaminated samples were inoculated
into a mycobacterial growth indicator tube (MGIT 960
system; Becton Dickinson, Sparks, MD) and also into 3%
Ogawa agar (Shinyang, Seoul, Korea). All positive cultures
were subjected to AFB smear to confirm the presence of
AFB and to exclude contamination. In addition, positive
liquid cultures were confirmed by both the presence of
cord formation and by MPT64 antigen testing (SD
BIOLINE TB Ag MPT64 Rapid; Standard Diagnostics
Figure 1 Flow diagram outlining patient enrollment and stratification for the analysis of the diagnostic performance of the assay.
Abbreviations: DST, drug susceptibility testing; MTB, Mycobacterium tuberculosis; NTM, nontuberculous mycobacteria; RIF, rifampin.
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Inc., Yongin-si, Gyeonggi-do, South Korea). If any of
these tests yielded a negative result, an rpoB-specific
PCR test using the MTB-ID V3 kit (YD Diagnostics,
Yongin-si, Gyeonggi-do, South Korea) was performed
to differentiate between MTB and NTM. Positive
cultures found only on solid medium were also con-
firmed by conventional PCR testing.
Detection of rifampin resistance
All MTB isolates were tested for resistance to RIF using the
MGIT 960 system, and were also referred to the Korean
Institute of Tuberculosis for conventional DST using the
absolute concentration method with Löwenstein-Jensen
medium [14,15]. The critical concentrations for RIF resist-
ance were 1.0 μg/mL and 40 μg/mL in the MGIT 960 sys-
tem and the absolute concentration method, respectively.
For all isolates yielding discrepant results, the rpoB gene
was sequenced [16,17].
Statistical analysis
The sensitivity, specificity, positive predictive value (PPV),
and negative predictive value (NPV) of the assay were cal-
culated for each category. These parameters were based
on the results from two reference methods, a concurrent
culture test and DST using the absolute concentration
method.
Statistical analyses were performed using SPSS software,
version 21.0 (SPSS Inc., Chicago, IL) and the VassarStats
website (http://vassarstats.net/).
Results
After exclusion of nine nonrespiratory specimens and 86
samples for which cultures were not requested at the
same day, a total of 303 respiratory specimens (264 spu-
tum samples and 39 samples of bronchial washing or
bronchoalveolar lavage fluid) from 300 patients were
used to analyze the diagnostic performance of the assay.
The median age of patients was 58 years (range, 18–93
years); 197 (65.7%) patients were male. Only one subject
was infected with HIV.
A total of 109 (36.0%) of the 303 samples were smear-
positive, while 194 were smear-negative, including 15
trace results and 179 negative results. Furthermore, 119
(39.3%) samples were positive for MTB according to the
Xpert assay, whereas 104 samples (34.3%) gave positive
culture results for MTB.
The overall performance of the Xpert assay and its per-
formance according to sample smear status are shown in
Table 1. When the 32 culture-negative samples from pa-
tients who were currently receiving tuberculosis treat-
ment, in the 60 days prior to testing and started >48 hours
ago, were excluded from analysis [3], the overall sensitiv-
ity, specificity, PPV, and NPV (95% confidence interval
[CI]) of the Xpert assay were 91.3% (83.8-95.7%), 94.0%
(89.0-96.9%), 90.5% (82.8-95.1%), and 94.6% (89.6-97.3%),
respectively (Table 1). The sensitivity in smear-positive
specimens was 96.2% (95% CI, 88.5-99.0%), but 76.0%
(95% CI, 54.5-89.8%) in smear-negative specimens.
The overall performance of the Xpert assay and its per-
formance according to its clinical application are shown in
Table 2. Variable performance of Xpert assay was observed
between categories. The sensitivity of the Xpert assay for
MTB detection in category 1 was 89.8% (95% CI, 78.5-
95.8%) but was 66.7% (95% CI, 12.5-98.2%) in category 2.
Only 3 samples in category 2 were culture-positive and 5
samples were smear-positive: 1 sample of grade 4, 1 sam-
ple of grade 2, and 3 samples of grade 1. The PPV of the
assay ranged from 33.3% (95% CI, 6.0-75.9%) in category 2
to 91.3% and 91.7% in categories 1 and 3, respectively. The
lower specificity and PPV of the assay when used for cat-
egory 4 samples was likely due to the tuberculosis treat-
ment that the patients were receiving (53/63, 84.1%). A
total of 14 false positive samples were all from patients
who were currently receiving tuberculosis treatment. Of
these, 8 samples (57%) were smear-positive: 1 sample of
grade 3, 4 samples of grade 2, and 3 samples of grade 1.
NPVs were over 90% in all categories.
Table 1 Performance of the Xpert MTB/RIF assay as stratified by smear status
Performance of the Xpert MTB/RIF assay Total (n =303) Total (n =271)a Smear result (total, n =271)a
No./Total no.% (95% CI) Smear-positive (n =100) Smear-negative (n =171)
Sensitivity
95/104 95/104 76/79 19/25
91.3 (83.8-95.7) 91.3 (83.8-95.7) 96.2 (88.5-99.0) 76.0 (54.5-89.8)
Specificity
175/199 157/167 18/21 139/146
87.9 (82.4-92.0) 94.0 (89.0-96.9) 85.7 (62.6-96.2) 95.2 (90.0-97.9)
PPV
95/119 95/105 76/79 19/26
79.8 (71.3-86.4) 90.5 (82.8-95.1) 96.2 (88.5-99.0) 73.1 (51.9-87.6)
NPV
175/184 157/166 18/21 139/145
95.1 (90.6-97.6) 94.6 (89.6-97.3) 85.7 (62.6-96.2) 95.9 (90.8-98.3)
Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
aExcluding the 32 culture-negative samples from patients who were currently receiving anti-tuberculosis treatment.
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Drug susceptibility culture results were available for 98
of the 104 MTB culture-positive samples, with 7 isolates
(7.1%) resistant to RIF. The Xpert assay correctly de-
tected RIF resistance in 6 out of the 7 resistant samples.
Thus, the sensitivity of the Xpert assay was 85.7%. The
assay also yielded one false positive result for RIF resist-
ance. Therefore, the specificity of the assay was 98.9%
(Table 3). Of the two specimens exhibiting a discrepancy
between the Xpert assay and the phenotypic DST re-
sults, one isolate was identified as RIF-resistant by the
Xpert assay but was phenotypically susceptible. Sequen-
cing of the rpoB gene from this isolate identified a muta-
tion at locus 516 (Asp→Tyr). The other isolate, which
was phenotypically resistant and did not have an rpoB
gene mutation as assessed by the Xpert assay, was re-
vealed by sequencing to be consistent with the wild-type
strain.
Discussion
Recent studies have highlighted the need for evaluating
the performance of the Xpert assay in different settings,
such as areas with different incidences of tuberculosis
and different levels of medical resource [18-20]. These
evaluations are important for determining whether the
Xpert assay is transferrable to different settings. Sohn et al.
reported that the impact of Xpert assay in a low-
incidence, high-resource ambulatory setting is limited
[18]. The present study was performed in South Korea, a
country with an intermediate tuberculosis burden and a
high level of medical resources. The results presented
here demonstrate that the Xpert assay does not perform
equally well for all clinical applications of MTB detec-
tion. A previous study reported that the Xpert assay per-
formed equally well among patients with and without
presumptive tuberculosis in a country highly endemic
for tuberculosis [8]. These authors suggested the use of
the Xpert assay as routine tuberculosis screening. How-
ever, in the present study, significant differences in the
performance of the Xpert assay were observed when it
was used to test samples from patients with a high prob-
ability of pulmonary tuberculosis (category 1) and those
in clinically indeterminate category 2. A low PPV was
noted in the low prevalence population group (category
2). Of the six positive samples, four (66.7%) were false
positives (Xpert assay positive and culture-negative); all
of the semi-quantitative results given by the Xpert assay
were “Very Low” (n =3) or “Low” (n =1). This suggests
the limited potential impact of Xpert assay to detect
MTB in patients with a low probability of pulmonary tu-
berculosis in an intermediate burden setting where (1)
routine laboratory smear and culture procedures are per-
formed according to the standard diagnostic algorithm;
(2) nucleic acid amplification tests (NAATs) in the la-
boratory performs well; and (3) experienced physicians
care for tuberculosis patients. However, the Xpert assay
showed superior specificity and a better NPV for cat-
egory 2 samples compared with category 1 samples.
Therefore, the Xpert assay is a suitable tool for the
Table 2 Performance of the Xpert MTB/RIF assay as stratified by clinical application
Performance of the Xpert MTB/RIF assay Total (n =303) Clinical application
No./Total no.% (95% CI)
Category 1 Category 2 Category 3 Category 4
(n =118) (n =103) (n =19) (n =63)
Sensitivity
95/104 53/59 2/3 11/11 29/31
91.3 (83.8-95.7) 89.8 (78.5-95.8 ) 66.7 (12.5-98.2) 100 (67.9-100) 93.5 (77.2-98.9)
Specificity
175/199 54/59 96/100 7/8a 18/32
87.9 (82.4-92.0) 91.4 (80.3-96.8) 96.0 (89.5-98.7) 87.5 (46.7-99.3) 56.3 (37.9-73.2)
PPV
95/119 53/58 2/6 11/12a 29/43
79.8 (71.3-86.4) 91.4 (80.3-96.8) 33.3 (6.0-75.9) 91.7 (59.8-99.6) 67.4 (51.3-80.5)
NPV
175/184 54/60 96/97 7/7 18/20
95.1 (90.6-97.6) 90.0 (78.8-95.9) 99.0 (93.6-99.9) 100 (56.1-100) 90.0 (66.9-98.2)
Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
aOne false positive sample showed no growth in mycobacterial culture.
Table 3 Performance of the Xpert MTB/RIF assay in the detection of rifampin resistance
Rifampin resistance
Performance of the Xpert MTB/RIF assay
Sensitivity Specificity PPV NPV
Total (n =98)
No./Total no.% (95% CI)
6/7 90/91 6/7 90/91
85.7 (42.0-99.2) 98.9 (93.2-99.9) 85.7 (42.0-99.2) 98.9 (93.2-99.9)
Abbreviations: CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value.
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exclusion of tuberculosis in patients with a low
probability of pulmonary tuberculosis.
In our study, the sensitivity (91.3%) of the Xpert assay
for the diagnosis of pulmonary tuberculosis was compar-
able to the pooled sensitivity (89%; 95% credible interval
[CrI], 85-92%) in a recent meta-analysis [21]. As ex-
pected, a higher proportion of smear-negative results
(6/9) in Xpert-negative and culture-positive specimens
were noted in our study, consistent with what has
been reported previously [22]. With regard to specifi-
city, 10 specimens were Xpert-positive and culture-
negative. Five of these specimens were positive by at least
one other NAAT, or culture-positive using a follow-up
culture specimen.
Phenotypic DST is the gold standard, and has hitherto
not been questioned [23]. However, concerns have been
raised that some phenotypic DST methods are limited in
their detection of certain rpoB mutations that result in RIF
resistance [24-26]. In this study, 7 isolates were identified
as RIF-resistant by the Xpert assays; 6 of these isolates had
confirmed resistance according to culture-based DST.
Sequencing of the rpoB gene of the isolate with the dis-
crepant result revealed a mutation (Asp516Tyr) that had
recently been suggested to be associated with increased
treatment failure or relapse rates [24]. This finding sug-
gests that the use of phenotypic DST as the gold standard
for RIF resistance should be reconsidered, in the light of
our confirmation of the Xpert assay.
The frequency of isolation of NTM from clinical speci-
mens has shown a continuous increase in Korea [27-30].
A high specificity value is indispensable in order to dis-
criminate MTB from NTM in smear-positive samples
especially in countries with a high percentage of NTM
isolates [6]. Furthermore, rapid discrimination between
MTB and NTM can significantly decrease airborne in-
fection isolation time for individuals hospitalized without
active tuberculosis [31,32]. In this respect, our study re-
vealed that Xpert assay in smear-positive samples well-
discriminated MTB from NTM without cross-reactivity
with NTM species, albeit the small sample number.
The present study did have some limitations. First, this
was a retrospective study in routine clinical practice at a
single institution. Majority of the AFB smear were per-
formed only in specimen for culture. Nevertheless, the
retrospective design allowed us to understand the real
situation regarding the implementation of the Xpert assay
in routine clinical laboratories. Second, the strength of our
findings might be somewhat limited by the small numbers
of positive results, particularly in categories 2 and 3. To
strengthen our results, prospective studies in these patient
groups would be needed. However, this study successfully
provided a foundation for the design of more comprehen-
sive studies to evaluate the performance of Xpert assay
with respect to its clinical application.
Conclusion
The retrospective study present here revealed that the
Xpert assay exhibited variable performance according to
its clinical application in an intermediate-incidence,
high-resource setting. The finding in this study cautions
that careful interpretation for the results of this assay
would be needed in the light of the intended purpose of
the test.
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